Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Recent studies have demonstrated a loss of cannabinoid CB 1 receptors in the postmortem basal ganglia of patients affected by Huntington's disease (HD) and in transgenic mouse models for this disease. These studies have led to the notion that substances that increase the endocannabinoid activity, such as receptor agonists or inhibitors of endocannabinoid uptake and/or metabolism, might be useful in the treatment of hyperkinetic symptoms of this disease. In the present study, we employed a rat model of HD generated by bilateral intrastriatal injections of 3‐nitropropionic acid (3‐NP), a toxin that selectively damages striatal GABAergic efferent neurons. These rats exhibited biphasic motor disturbances, with an early (1–2 weeks) hyperactivity followed by a late (3–4 weeks) motor depression. Analysis of GABA, dopamine, and their related enzymes, glutamic acid decarboxylase and tyrosine hydroxylase, in the basal ganglia proved marked decreases compatible with the motor hyperkinesia. In addition, mRNA levels for CB 1 receptor, neuronal‐specific enolase, proenkephalin, and substance P decreased in the caudate‐putamen of 3‐NP‐injected rats. There were also reductions in CB 1 receptor binding in the caudate putamen, the globus pallidus, and, to a lesser extent, the substantia nigra. By contrast, mRNA levels for tyrosine hydroxylase in the substantia nigra remained unaffected. Interestingly, the administration of AM404, an inhibitor of endocannabinoid uptake, to 3‐NP‐injected rats attenuated motor disturbances observed in the early phase of hyperactivity. Administration of AM404 also tended to induce recovery from the neurochemical deficits caused by the toxin in GABA and dopamine indices in the basal ganglia. In summary, morphological, behavioral, and biochemical changes observed in rats intrastriatally lesioned with 3‐NP acid were compatible with a profound degeneration of striatal efferent GABAergic neurons, similar to that occurring in the brain of HD patients. As expected, a loss of CB 1 receptors was evident in the basal ganglia of these rats. However, the administration of substances that increase endocannabinoid activity, by inhibiting the uptake process, allowed an activation of the remaining population of CB 1 receptors, resulting in a significant improvement of motor disturbances and neurochemical deficits. These observations might be relevant to the treatment of hyperkinetic symptoms in HD, a human disorder with unsatisfactory symptomatic treatment for most patients. Synapse 44:23–35, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 5×
“These effects of cannabinoids are likely to be mediated by cannabinoid CB1 receptors, which are densely distributed in the basal ganglia (Herkenham et al., 1991a,b; Mailleux and Vanderhaeghen, 1992; Tsou et al., 1998).”
BackgroundMethodInfluentialImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Mezey, É., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M., & Szallasi, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3655 · Cited by 850 · cited 1×
“These receptors have been recently reported to be located in brain regions including the basal ganglia (Mezey et al., 2000).”
BackgroundThe endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
Brouillet, E., Jenkins, B. G., Hyman, B. T., Ferrante, R. J., Kowall, N. W., Srivastava, R., Roy, D. S., Rosen, B. R., & Beal, M. F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05859.x · Cited by 367 · cited 5×
“…the mechanism of action of this toxin and how 3-NP-induced striatal lesions closely mimic the anatomical, behavioral, and neurochemical pathology seen in HD (Beal et al., 1993; Brouillet et al., 1993; Borlongan et al., 1995, 1997; Guyot et al., 1997; Reynolds et al., 1997; Alexi et al., 1998).”
BackgroundMethodResultInfluentialThe anandamide transport inhibitor AM404 activates vanilloid receptors
Zygmunt, P. M., Chuang, H.-H., Movahed, P., Julius, D., & Högestätt, E. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00207-7 · Cited by 270 · cited 3×
“This means that AM404, by itself (Zygmunt et al., 2000) or through its anandamide-potentiating effect (Smart et al., 2000), may activate VR1 receptors.”
Background
Cited by
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Self-citationWallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393
Endovanilloids: Putative endogenous ligands of transient receptor potential vanilloid 1 channels
van der Stelt, M., & Di Marzo, V. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04081.x · Cited by 389
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
van der Stelt, M., & Di Marzo, V. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 291
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
Self-citationSagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22682 · Cited by 105
“…administration of specific cannabinoids has proven neuroprotective effects in HD (Pazos et al., 2008), which adds to their ability to contribute to the suppression of certain motor symptoms (e.g., hyperkinetic movements) because of their hypokinetic profile (Lastres-Becker et al., 2002, 2003).”
BackgroundSelf-citationRole of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats
RAWLS, S., DING, Z., & COWAN, A. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.03.011 · Cited by 35
Metadata
- Authors
- Lastres‐Becker, I., Hansen, H. H., Berrendero, F., De Miguel, R., Pérez‐Rosado, A., Manzanares, J., Ramos, J. A., & Fernández‐Ruiz, J.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2002-01-30
- Volume
- 44
- Issue
- 1
- Pages
- 23-35
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2029651427
- Cited by
- 117
- References
- 6
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.